New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 12, 2004, Pages 791-796

  Simon, Thorsten ^a   Spitz, Rüdiger ^a   Faldum, Andreas ^b   Hero, Barbara ^a   Berthold, Frank ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Chromosome 11q; Chromosome 1p; Deletion; Imbalance; Localized neuroblastoma; Stage 4S neuroblastoma

Indexed keywords

LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHILD; CHROMOSOME 11Q; CHROMOSOME 1P; CHROMOSOME 3P; CHROMOSOME DELETION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE AMPLIFICATION; HISTOLOGY; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; NEWBORN; ONCOGENE MYC; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TUMOR LOCALIZATION;

ADOLESCENT; AGE FACTORS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; GENE AMPLIFICATION; HUMANS; INFANT; INFANT, NEWBORN; L-LACTATE DEHYDROGENASE; MALE; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 10944248244     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Schleiermacher G, Rubie H, Hartmann O, et al. Treatment of stage 4s neuroblastoma: report of 10 years' experience of the French Society of Paediatric Oncology (SFOP). Br J Cancer. 2003;89:470-476.
2. Hero B, Jobke A, Krause I, et al. Regression in localized infant neuroblastoma without cytotoxic treatment: first results of the prospective German trial NB95-S. Med Pediatr Oncol. 1998;31:194.
3. Cheung NK, Kushner BH, LaQuaglia MP, et al. Survival from non-stage 4 neuroblastoma without cytotoxic therapy, an analysis of clinical and biological markers. Eur J Cancer. 1997;33:2117-2120.
4. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med. 2002;346:1047-1053.
5. Yamamoto K, Ohta S, Ito E, et al. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol. 2002;20:1209-1214.
6. Sawada T, Matsumura T, Kawakatsu H, et al. Long-term effects of mass screening for neuroblastoma in infancy. Am J Pediatr Hematol Oncol. 1991;13:3-7.
7. Rubie H, Hartmann O, Michon J, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Societe Française d'Oncologie Pediatrique. J Clin Oncol. 1997;15:1171-1182.
8. Berthold F, Sahin K, Hero B, et al. The current contribution of molecular factors to risk estimation in neuroblastoma patients. Eur J Cancer. 1997;33:2092-2097.
9. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313:1111-1116.
10. Matthay KK, Sather HN, Seeger RC, et al. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol. 1989;7:236-244.
11. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group study. J Clin Oncol. 2000;18:18-26.
12. Maris JM, Guo C, White PS, et al. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Med Pediatr Oncol. 2001;36:24-27.
13. Caron H, van Sluis P, van Hoeve M, et al. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. Nat Genet. 1993;4:187-190.
14. Guo C, White PS, Weiss MJ, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene. 1999;18:4948-4957.
15. Hallstensson K, Thulin S, Aburatani H, et al. Representational difference analysis and loss of heterozygosity studies detect 3p deletions in neuroblastoma. Eur J Cancer. 1997;33:1966-1970.
16. Eggert A, Ikegaki N, Liu X, et al. Prognostic and biological role of neurotrophin-receptor TrkA and TrkB in neuroblastoma. Klin Padiatr. 2000;212:200-205.
17. Kramer K, Cheung NK, Gerald WL, et al. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma. Eur J Cancer. 1997;33:2098-2100.
18. Krams M, Hero B, Berthold F, et al. Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma. Am J Pathol. 2003;162:1019-1026.
19. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477.
20. Berthold F, Hero B, Kremens B, et al. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett. 2003;197:11-17.
21. Spitz R, Hero B, Ernestus K, et al. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Med Pediatr Oncol. 2003;41:30-35.
22. Spitz R, Hero B, Westermann F, et al. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations. Genes Chromosomes Cancer. 2002;34:299-305.
23. Spitz R, Hero B, Ernestus K, et al. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res. 2003;9:52-58.
24. Collett D. Strategy for model selection. Modelling Survival Data in Medical Research. London: Chapman and Hall, 1994:78-83.
25. De Bernardi B, Conte M, Mancini A, et al. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma. J Clin Oncol. 1995;13:884-893.